NEW YORK (GenomeWeb News) – Massachusetts General Hospital, the Broad Institute, and Amgen are collaborating to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease, the partners said today.

While scientists have identified more than 150 regions of the genome that place a person at risk for developing IBD, treatments that make use of this knowledge are "urgently needed," the partners said, noting that recently developed IBD drugs are not always effective and can cause significant side effects in some patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.